The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Open accessAbstract
BACKGROUND There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody, was efficacious and well tolerated as induction therapy. Here, we report the efficacy and safety of subcutaneous risankizumab as maintenance therapy. METHODS FORTIFY is a phase 3, multicentre, randomised, double-blind, placebo-controlled, maintenance withdrawal study across 273 clinical centres in 44 countries across North and South America, Europe, Oceania, Africa, and the Asia-Pacific region that enrolled participants with clinical response to risankizumab in the ADVANCE or MOTIVATE induction studies. Patients in ADVANCE or MOTIVATE were aged 16-80 years with moderately to severely active Crohn's disease. Patients in the FORTIFY substudy 1 were randomly assigned again (1:1:1) to receive either subcutaneous risankizumab 180 mg, subcutaneous risankizumab 360 mg, or withdrawal from risankizumab to receive subcutaneous placebo (herein referred to as withdrawal [subcutaneous placebo]). Treatment was given every 8 weeks. Patients were stratified by induction dose, post-induction endoscopic response, and clinical remission status. Patients, investigators, and study personnel were masked to treatment assignments. Week 52 co-primary endpoints were clinical remission (Crohn's disease activity index [CDAI] in the US protocol, or stool frequency and abdominal pain score in the non-US protocol) and endoscopic response in patients who received at least one dose of study drug during the 52-week maintenance period. Safety was assessed in patients receiving at least one dose of study medication. This study is registered with ClinicalTrials.gov, NCT03105102. FINDINGS 712 patients were initially assessed and, between April 9, 2018, and April 24, 2020, 542 patients were randomly assigned to either the risankizumab 180 mg group (n=179), the risankizumab 360 mg group (n=179), or the placebo group (n=184). Greater clinical remission and endoscopic response rates were reached with 360 mg risankizumab versus placebo (CDAI clinical remission was reached in 74 (52%) of 141 patients vs 67 (41%) of 164 patients, adjusted difference 15% [95% CI 5-24]; stool frequency and abdominal pain score clinical remission was reached in 73 (52%) of 141 vs 65 (40%) of 164, adjusted difference 15% [5-25]; endoscopic response 66 (47%) of 141 patients vs 36 (22%) of 164 patients, adjusted difference 28% [19-37]). Higher rates of CDAI clinical remission and endoscopic response (but not stool frequency and abdominal pain score clinical remission [p=0·124]) were also reached with risankizumab 180 mg versus withdrawal (subcutaneous placebo; CDAI clinical remission reached in 87 [55%] of 157 patients, adjusted difference 15% [95% CI 5-24]; endoscopic response 74 [47%] of 157, adjusted difference 26% [17-35]). Results for more stringent endoscopic and composite endpoints and inflammatory biomarkers were consistent with a dose-response relationship. Maintenance treatment was well tolerated. Adverse event rates were similar among groups, and the most frequently reported adverse events in all treatment groups were worsening Crohn's disease, arthralgia, and headache. INTERPRETATION Subcutaneous risankizumab is a safe and efficacious treatment for maintenance of remission in patients with moderately to severely active Crohn's disease and offers a new therapeutic option for a broad range of patients by meeting endpoints that might change the future course of disease. FUNDING AbbVie.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Self-citationDaperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Self-citationACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Self-citationIL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
Geremia, A., Arancibia-Cárcamo, C. V., Fleming, M. P. P., Rust, N., Singh, B., Mortensen, N. J., Travis, S. P. L., & Powrie, F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101712 · Cited by 640
Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F., & Pallone, F. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70128-8 · Cited by 573
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease
Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M. T., Nakazawa, A., Sugita, A., Koganei, K., et al. (2008) · Gut · doi:10.1136/gut.2007.135053 · Cited by 570
Self-citationD'Haens, G., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00467-6 · Cited by 433
Self-citationJones, J., Loftus, E. V., Panaccione, R., Chen, L., Peterson, S., Mcconnell, J., Baudhuin, L., Hanson, K., Feagan, B. G., Harmsen, S. W., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.010 · Cited by 414
Self-citationGisbert, J. P., Marín, A. C., McNicholl, A. G., & Chaparro, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13083 · Cited by 323
Cited by
Dolinger, M., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 580
D'Haens, G., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00467-6 · Cited by 433
Self-citationECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
D’Haens, G., Dubinsky, M., Kobayashi, T., Irving, P. M., Howaldt, S., Pokrotnieks, J., Krueger, K., Laskowski, J., Li, X., Lissoos, T., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2207940 · Cited by 361
Self-citationIL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Verstockt, B., Salas, A., Sands, B. E., Abraham, C., Leibovitzh, H., Neurath, M. F., Vande Casteele, N., Alimentiv Translational Research Consortium (ATRC), Danese, S., D’Haens, G., et al. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00768-1 · Cited by 261
Self-citation
Metadata
- Authors
- Ferrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., Lindsay, J. O., Loftus, E. V., Panés, J., Peyrin-Biroulet, L., Ran, Z., Rubin, D. T., Sandborn, W. J., Schreiber, S., Neimark, E., Song, A., Kligys, K., Pang, Y., Pivorunas, V., Berg, S., Duan, W. R., Huang, B., Kalabic, J., Liao, X., Robinson, A., Wallace, K., & D'Haens, G.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 399
- Issue
- 10340
- Pages
- 2031-2046
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4281924689
- Cited by
- 345
- References
- 21
- FWCI
- 37.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00466-4
- The paper
- Ferrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., Lindsay, J. O., Loftus, E. V., Panés, J., Peyrin-Biroulet, L., Ran, Z., Rubin, D. T., Sandborn, W. J., Schreiber, S., Neimark, E., . . . D'Haens, G. (2022). Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)00466-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.